ADVERTISEMENT
Psychedelics Business Briefs: Delix, Numinus, Ketamine Wellness Centers
Delix Therapeutics Announces New Head of R&D
Delix Therapeutics has announced the appointment of Eliseo Salinas, MD, MSc, as its first head of research and development. The company said in a news release that in his new role, Dr Salinas will support “the continued acceleration and expansion” of its preclinical and clinical pipeline of non-hallucinogenic, neuroplasticity-promoting psychoplastogens.
Most recently, Dr Salinas served as head of research and development at Passages Bio, where he focused on advancing gene therapies for the treatment of central nervous system (CNS) disorders. He has also served as chief scientific officer at Acadia Pharmaceuticals, head of research and development and chief scientific officer at Shire, head of development and chief medical officer at Elan Pharmaceuticals, and head of worldwide CNS development at Wyeth.
Numinus Opens New Montreal Clinic, Expands Offerings
Numinus Wellness has opened a new clinic in Montreal that will replace an existing clinic located in the city’s downtown area. The new site in the Plateau neighborhood will expand capacity to offer ketamine treatments, including a wider range of ketamine-assisted therapy options.
Expanded services will also include different administrations of ketamine, along with options in treatment length and session type. Currently, Numinus offers a 6-week program for indications including depression, addiction, and trauma and anxiety. Ketamine will now be offered as a standalone treatment, allowing Numinus clients to complement prior ketamine-assisted therapy, use it as an emergency antidepressant, or use it in conjunction with therapy from another provider.
Numinus now operates 13 clinics across the United States and Canada.
Ketamine Wellness Centers Expands Partnership With Veterans Administration
Ketamine Wellness Centers (KWC), a subsidiary of Delic Holdings Corporation, announced on Thursday that it has expanded its partnership with the Veterans Administration Community Care Network (VA-CCN) to cover treatments with the esketamine nasal spray Spravato at select clinics. Through the agreement, VA-CCN patients diagnosed with treatment-resistant depression will have access to treatments with prior authorization from the VA-CCN at 9 clinics across 5 states.
The new agreement builds upon an existing partnership between KWC and the VA-CCN to offer treatment for veterans experiencing post-traumatic stress disorder (PTSD), major depression, and chronic pain at KWC facilities in Illinois and Minnesota.
References
